Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121151 | 1.00 | LMNA (0.47) | LMNAALDH1A1THRBPDE4APDE4B | |
| SCHEMBL4120857 | 0.90 | APP (0.42) | LMNAALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL4120863 | 0.90 | APP (0.42) | LMNAALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL3915937 | 0.88 | KDM4E (0.39) | LMNAALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL3915941 | 0.88 | KDM4E (0.39) | LMNAALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL3920316 | 0.88 | ALDH1A1 (0.54) | LMNAALDH1A1APPKDM4EMEN1 | |
| SCHEMBL3920312 | 0.88 | ALDH1A1 (0.54) | LMNAALDH1A1APPKDM4EMEN1 | |
| SCHEMBL3919193 | 0.87 | APP (0.38) | LMNAALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL3919196 | 0.87 | APP (0.38) | LMNAALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL646477 | 0.86 | MAOA (0.36) | LMNAALDH1A1APPKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | LMNA 4825/4885ALDH1A1 2621/4885THRB 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.